MAP2K7 and neoplasm: Since sorafenib targets the Ras/Raf/MEK/ERK pathway which is also involved in regulating energy metabolism in cancer cells [8], we hypothesized that treatment could reduce tumor metabolism and viability almost immediately upon initiation of treatment.